

24 June 2025

The Manager Companies  
ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

(2 pages by email)

Dear Madam,

### **HEPATITIS B VIRUS PROGRAM UPDATE**

The Directors of Biotron Limited ('Biotron' or 'the Company') (ASX: BIT) are pleased to advise that the first stage of the animal study of Biotron's lead drug for Hepatitis B Virus (HBV) is complete.

The first stage of the animal study was a safety study, set up to determine the correct dosage of the drug for use in the second stage in which the mice will be challenged with HBV.

The aim of the study is the assessment of the antiviral activity of Biotron's HBV drug in two mouse HBV models that are commonly used to study liver diseases and infection.

In the first, completed, stage mice were dosed every 10 hours for 7 days with three different doses of the drug to determine safe doses. All mice remained healthy throughout the study, and no gross organ toxicity was observed on autopsy, confirming the safety of the drug in the mice at the dosing levels tested.

Biotron's HBV drug will now be assessed for its ability to protect and treat HBV infection in these two mouse models. One model (MUP-uPA-SCID mice) will generate data on the effect of the drug on the early stages of infection with HBV. The second model (TG05-C57Bl/6) will generate data on the effect of the drug on late stages of infection with HBV.

Biotron's HBV program is at an important stage of development, and funds were raised in the recent rights issue to progress the lead HBV compounds into an animal model of disease.

Like HIV-1, HBV can be treated with drugs that stop the virus replicating, but these do not eradicate the virus. Biotron has designed and tested a novel set of compounds to target HBV. Several have demonstrated significant anti-viral activity against HBV in pre-clinical studies in cell-cultures, reducing levels of cccDNA (covalently closed circular DNA), as well as other key viral markers.

For personal use only


Chronic infection with HBV can lead to complications such as cirrhosis and liver cancer, which cause close to one million deaths worldwide each year. Over 2 billion people worldwide have been infected with HBV. The World Health Organisation estimates that over 250 million are chronically infected.

The progression of one of several Biotron compounds with promising anti-HBV activity into an animal model of disease is an important step for this program.

The study is in progress at the SCRIPPS Research Institute, La Jolla, CA, USA.

In parallel with completing the above HBV animal study, the Company is continuing its commercialisation activities in collaboration with the US-based C14 Consulting Group. The recent Biotechnology Industry Organisation annual meeting (BIO2025) in Boston, MA, USA provided an opportunity for face-to-face meetings with potential partners. Discussions and sharing of detailed information on Biotron programs, with a focus on HIV-1, are ongoing.

Yours sincerely



Marcelo Mora  
Company Secretary

pjn12660

This announcement has been approved by the Company's Managing Director.

### **About Biotron**

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional promising preclinical programs including HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

### **Enquiries**

Dr Michelle Miller  
Managing Director  
Biotron Limited  
+61-(0)412313329

[mmiller@biotron.com.au](mailto:mmiller@biotron.com.au)

Rudi Michelson  
Monsoon Communications  
+61-3 9620 3333